$1.6 Billion Financing Announced for Nordic Capital’s Acquisition of ADVANZ PHARMA

Paul Hastings LLP, a leading global law firm, announced today that it has represented Barclays, Goldman Sachs, Intesa SanPaolo, J.P. Morgan, Jefferies, Morgan Stanley and Royal Bank of Canada in connection with a $1,580 million equivalent financing package in relation to private equity firm Nordic Capital’s acquisition of ADVANZ PHARMA Corp. Limited by means of a scheme of arrangement under Article 125 of the Companies (Jersey) Law 1991 (as amended).

The financing package comprises: (a) a senior multi-currency revolving credit facility in a euro-equivalent amount equal to $200 million; (b) a senior term loan facility in a euro-equivalent amount equal to $360 million; (c) Reg S/Rule 144A senior secured notes in a euro-equivalent amount equal to $560 million; and (d) S/Rule 144A senior secured notes in a sterling-equivalent amount equal to $460 million.

ADVANZ PHARMA an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with continued access to high-quality, niche established medicines.

The Paul Hastings team in London was led by partner Luke McDougall, together with M&A partner Roger Barron, finance partners Peter Hayes, Richard Kitchen, Ed Holmes and tax partner Jiten Tank with finance associates Amin Doulai, Alon Blitz, Carlos Ruiz, Andrew Lowndes, Charlotte Rice, Andro Atlaga and Lorenzo Colombi-Manzi and tax associate Abigail Hung assisting.